Role of Piperacillin/Tazobactam in Mass Bacteremia
Recommendations for Use in Bacteremia
- The European Respiratory Society and Intensive Care Medicine recommend piperacillin/tazobactam as an appropriate empiric therapy for mass bacteremia, but it should be used as part of combination therapy with an aminoglycoside or fluoroquinolone in patients with septic shock or at high risk for multidrug-resistant organisms 1, 2
- For patients with mass bacteremia without septic shock and low risk for MDR pathogens, piperacillin/tazobactam monotherapy is appropriate as initial empiric therapy, according to the European Respiratory Journal 2
- Combination therapy with piperacillin/tazobactam plus an aminoglycoside or an antipseudomonal fluoroquinolone is recommended for patients with mass bacteremia with septic shock or at high risk for MDR pathogens, as stated in Intensive Care Medicine and European Respiratory Journal 1, 2
Risk Factors Requiring Broader Coverage
- Prior intravenous antibiotic use within 90 days is a risk factor requiring broader coverage, as noted in Clinical Infectious Diseases 3
- Septic shock at time of presentation is a risk factor requiring broader coverage, according to Clinical Infectious Diseases 3
- Five or more days of hospitalization prior to bacteremia is a risk factor requiring broader coverage, as stated in Clinical Infectious Diseases 3
- Healthcare-associated or nosocomial infection is a risk factor requiring broader coverage, as noted in Journal of Hepatology 4
- Known colonization with multidrug-resistant organisms is a risk factor requiring broader coverage, according to Intensive Care Medicine 5
Treatment Duration and De-escalation
- De-escalation with discontinuation of combination therapy is recommended within the first few days in response to clinical improvement and/or evidence of infection resolution, as stated in Intensive Care Medicine 1
- Treatment should be guided by culture results and antimicrobial susceptibility testing when available, according to World Journal of Emergency Surgery 6
Special Considerations
- For healthcare-associated or nosocomial bacteremia, broader initial coverage may be needed due to higher risk of resistant organisms, as noted in Journal of Hepatology 4